XEFO 8MG 10TAB

18.60 EGP

one film – coated tablet contains 8 mg lornoxicam .

If you purchase this product you will earn 1 Point worth of 0.01 EGP!

XEFO 8MG 10TAB; lornoxicam, anti inflammatory agents .

ACTIVE-INGREDIENT OF XEFO 8MG 10TAB

one film – coated tablet contains 8 mg lornoxicam .

INDICATION OF XEFO 8MG 10TAB

short-term relief of acute mild to moderate pain . symptomatic relief of pain and inflammation in osteoarthritis . Symptomatic of pain and inflammation in rheumatoid

DOSAGE OF XEFO 8MG 10TAB

Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box .

The recommended dose is : –

for all patients the appropriate dosing regimen should be based upon individual response to treatment undesirable effects may be minimized by using the lowest effective dose for the shortest duration necessary to control the symptoms . Pain 8-16 mg lornoxicam daily divided into 2 or 3 doses . maximum recommended daily dose is 16 mg . osteoarthritis and rheumatoid arthritis : intial recommended dose is 12 mg 12 mg lornoxicam daily divided into 2 or 3 doses . maintenance dose should not exceed 16 mg lornoxicam daily . xefo film – coated tablets are supplied for oral use and should be taken with a sufficient quantity of liquid . additional information about special population : hepatic impairment : for patients with moderate hepatic impairment the maximum recommended daily dose is 12 mg divided in 2 or 3 doses . renal impairment : dosage adjustments should be considered in patients with renal insufficiency because these patients have an increased susceptibility to renal side effects due to dependency on renal prostaglandins for maintenance of renal blood flow . for patients with mild to moderate renal impairment the maximum recommended daily dose is 12 mg divided in 2 or 3 doses > children and adolescents : lornoxicam is not recommended for use in children and adolescent of age below 18 due to lack of data on safety and efficacy . elderly : no special dosage modification is required for elderly patients above age 65 unless renal or hepatic function is impaired . lornoxicam should be administered with precaution as gastrointestinal adverse effects are less well tolerated in this group >

OVER-DOSAGE OF XEFO 8MG 10TAB

at this time there is no experience of overdose to permit definition of the consequences of an overdose , or to suggest specific managements . However , it can be expected that after an overdose with lornoxicam , the following symptoms can be seen ; nausea , vomiting , cerebral symptoms (dizziness , disturbances in vision ) . severe symptoms re ataxia ascending to coma and cramps , liver and kidney damages and may be coagulation disorders . in the case of real or suspected overdose , the medicinal product should be withdrawn . due to its short half-life , lornoxicam is rapidly excreted . lornoxicam is not dialyzable . no specific antidote is known to date . the usual emergency measures including gastric lavage should be considered . based on principles , only administering activated charcoal immediately after the intake of lornoxicam can lead to diminished absorption of the preparation . gastrointestinal disorders can for example be treated a prostaglandin analogue or ranitidine .

CONTRA-INDICATION OF XEFO 8MG 10TAB

hypersensitivity to lornoxicam or any other excipients . Thrombocytopenia . Hypersensitivity 9 symptoms like asthma , rhinitis , angioedema or urticarial ) or other NSAIDs including acetyl salicytic acid . Severe heart failure . Gastrointestinal bleeding , cerebrovascular bleeding disorders . history of gastrointestinal bleeding or perforation related to previous NSAIDs therapy . active or history of recurrent peptic ulcer haemorrhage ( two or more distinct episodes of proven ulceration or bleeding ) severe hepatic impairment . severe renal impairment ( serum creatinine > 700 µmol/l equivalent to GFR less than 10 ml/ minute ) the third trimester in pregnancy .

STORAGE OF XEFO 8MG 10TAB

store at temperature not exceeding 30 C in dry place . Keep all medicines out of reach of children .
PACK OF XEFO 8MG 10TAB
carton box containing 1 strips each of 10 F.C tablets and inner leaflet .
XEFO 8MG 10TAB MANUFACTURED BY
MARCYRL FOR TAKEDA EGYPT FOR TRADING AND DISTRIBUTION UNDER LICENCE OF TAKEDA AUSTRIA .

https://www.medscape.com/viewarticle/532284_4

https://www.gardeniapharmacy.com/category/medicine-2/

Form

Gender

How to use

Reviews

There are no reviews yet.

Show reviews in all languages (1)

Be the first to review “XEFO 8MG 10TAB”

Your email address will not be published. Required fields are marked *

Shopping Cart
Don`t copy text!
Scroll to Top
Open chat